David R. Epstein - 13 Jul 2022 Form 4 Insider Report for Senti Biosciences, Inc. (SNTI)

Reporting relationship: Director
Issuer ticker: SNTI
Reported as of: 13 Jul 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jul 2022, 18:00:25 UTC
Prior SEC filing: 30 Jun 2022
Next SEC filing: 10 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Mike Rhee, attorney-in-fact

Key filing fact

David R. Epstein filed Form 4 for Senti Biosciences, Inc. (SNTI) on 15 Jul 2022.

Key facts

This page summarizes David R. Epstein's Form 4 filing for Senti Biosciences, Inc. (SNTI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jul 2022, 18:00.

Change

Previous filing in this sequence was filed on 30 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SNTI transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +125,000
Change %
Price: $0.000000
Shares after: 125,000
Date: 13 Jul 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,000
Exercise price: $1.75
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option vest in 36 substantially equal monthly installments over three years from July 13, 2022, subject to the reporting person's continued service through the applicable vesting date. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2022 Equity Incentive Plan with the U.S. Securities and Exchange Commission.

SEC remarks

Exhibit 24 - Power of Attorney